CEL-SCI's Multikine Gains Saudi FDA NADR Designation

PUBT · 2d ago
CEL-SCI's Multikine Gains Saudi FDA NADR Designation
  • CEL-SCI’s cancer immunotherapy Multikine received Saudi FDA NADR designation, qualifying it for accelerated regulatory review.
  • A marketing authorization application is planned within 2-3 months with Saudi partner Amarox.
  • Priority review targets 160 working days, supporting a potential launch in 2027 or early 2028, subject to approval.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CEL-SCI Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20261120334063) on November 20, 2026, and is solely responsible for the information contained therein.